% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Wesseling:304281,
      author       = {P. Wesseling and D. Capper$^*$ and G. Reifenberger and C.
                      Sarkar and C. Hawkins and A. Perry and B.
                      Kleinschmidt-DeMasters and T. Komori and W. Paulus and V.
                      Santosh and M. van den Bent and M. Weller and S. Pfister$^*$
                      and U. Tabori and D. Figarella-Branger and B. A. Orr and D.
                      N. Louis},
      title        = {c{IMPACT}-{NOW} update 11: {P}roposal on adaptation of
                      diagnostic criteria for {IDH}- and {H}3-wildtype diffuse
                      high-grade gliomas and for posterior fossa ependymal
                      tumors.},
      journal      = {Brain pathology},
      volume       = {nn},
      issn         = {1015-6305},
      address      = {Oxford},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2025-01821},
      pages        = {nn},
      year         = {2025},
      note         = {epub},
      abstract     = {The Consortium to Inform Molecular and Practical Approaches
                      to Central Nervous System Tumor Taxonomy (cIMPACT-NOW)
                      updates provide guidelines for the diagnosis of central
                      nervous system (CNS) tumors and suggestions for future World
                      Health Organization (WHO) classification. Following
                      publication of the fifth edition WHO Classification of CNS
                      Tumors (WHO CNS5) in 2021, the cIMPACT-NOW working group
                      'Clarification' reviewed WHO CNS5 and prioritized two topics
                      for further elucidation: (a) distinction of Glioblastoma,
                      IDH-wildtype from Diffuse pediatric-type high-grade glioma,
                      H3-wildtype, and IDH-wildtype and (b) clarification of
                      subgroups of posterior fossa (PF) ependymal tumors.
                      Recommendations regarding the IDH- and H3-wildtype diffuse
                      high-grade gliomas include: (1) use caution assigning CNS
                      WHO grade 4 (diagnosis of Glioblastoma, IDH-wildtype) to a
                      'TERT promoter only', histologically low-grade, IDH-wildtype
                      tumor; (2) EGFR gene amplification and +7/-10 chromosome
                      copy number alterations should not be used as solitary
                      defining features for diagnosing high-grade gliomas as
                      Glioblastoma, IDH-wildtype in patients <40 years of age; (3)
                      Diffuse pediatric-type high-grade glioma, H3-wildtype, and
                      IDH-wildtype should be considered in the differential
                      diagnosis in adults, especially those <40 years of age; (4)
                      PDGFRA alteration, EGFR alteration, or MYCN amplification
                      count as key molecular features of Diffuse pediatric-type
                      high-grade glioma, H3-wildtype, and IDH-wildtype only in
                      patients <25 years. Guidelines for improved diagnosis of
                      posterior fossa ependymal tumors include: (1)
                      immunohistochemical demonstration of nuclear EZHIP supports
                      classification as PF group A ependymoma; (2) a PF ependymoma
                      with retained nuclear H3 K27me3 expression and no nuclear
                      EZHIP overexpression for which DNA methylation profiling is
                      not performed should be considered as PF ependymoma, 'not
                      otherwise specified'; (3) for emerging tumors not included
                      in WHO CNS5, 'not elsewhere classified' (NEC) can be added
                      to the diagnosis. Of note, these recommendations are not
                      formal changes to the WHO definitions and diagnostic
                      criteria but are intended to provide diagnostic guidance in
                      advance of WHO CNS6.},
      keywords     = {Glioblastoma, IDH‐wildtype (Other) / WHO classification
                      (Other) / cIMPACT‐NOW (Other) / clarification (Other) /
                      diffuse pediatric‐type high‐grade glioma (Other) /
                      posterior fossa ependymoma (Other)},
      cin          = {BE01 / B062},
      ddc          = {610},
      cid          = {I:(DE-He78)BE01-20160331 / I:(DE-He78)B062-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40887057},
      doi          = {10.1111/bpa.70035},
      url          = {https://inrepo02.dkfz.de/record/304281},
}